מכפיל P/S עתידי: Beyond Air Inc (XAIR)

Beyond Air, Inc. (XAIR) generates revenue from the supply of LungFit PH systems to American neonatologists. The projected price-to-sales ratio reflects market expectations, where 0.40 serves as the base parameter value. Growth prospects are supported by autonomous devices that reduce the workload of medical staff, as well as the implementation of eco-friendly cylinder-free technologies and strict corporate security controls.

To objectively value Beyond Air, Inc. (XAIR), managers require a forward P/S ratio that correlates current market capitalization with expected revenue, eliminating market noise and speculative volatility. By analyzing the modeled P/S of Beyond Air, Inc. (XAIR), an investor determines the asset's fair value, which is critical when assessing the scaling of medical supplies and the logistical efficiency of delivering nitric oxide delivery systems to hospitals.